SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Bullish on SEPR ...
SEPR
|
|
|
+29.25%
in
455 days
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $22 Analysts' Targets Deutsche Bank Securities $23 Accumulate Wednesday, July 30, 2008 Friedman, Billings, Ramsey & C $17 Mkt Perform Friday, May 02, 2008 Susquehanna Financial $17 Negative Friday, May 02, 2008 AmTech Research $28 Buy Monday, April 07, 2008 UBS Securities $25 Reduce Monday, March 03, 2008
|
Bullish on SEPR ...
SEPR
|
|
|
+29.25%
in
455 days
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $22 Analysts' Targets Deutsche Bank Securities $23 Accumulate Wednesday, July 30, 2008 Friedman, Billings, Ramsey & C $17 Mkt Perform Friday, May 02, 2008 Susquehanna Financial $17 Negative Friday, May 02, 2008 AmTech Research $28 Buy Monday, April 07, 2008 UBS Securities $25 Reduce Monday, March 03, 2008
|
SEPR is a SELL
SEPR
From the Blogosphere
Sepracor gets a healthy buyout
Filed under: Deals, Japan  Lately, the Japanese pharma industry has flexed its M&A muscle, trying to find opportunities in global markets. And, the latest deal came this week: Dainippon Sumitomo Pharma agreed to shell out $2.6 billion for Sepracor Inc. (NASDAQ: SEPR). The deal is all-cash.
Why all the interest? There are several drivers. First, the strong yen has made deals fairly cheap. Next, the Japanese market is expected to be slow because of government mandates. And finally, Japanese pharma companies are coming up against expirations of major drugs. <><>Continue reading <>Sepracor gets a healthy...
|
Sepracor’s Great Value Recognized by Japan’s Dainippon Sumitomo
<>Sepracor (SEPR) shares surged up to 30% higher in early afternoon trading as news broke from the Nikkei of an approximately $2.71 billion offer from Dainippon Sumitomo. Sepracor’s stock has been hammered over the last few years, and recently there have been some disappointing clinical trial results. We wrote about one of these disappointing trials in early July (Study of Sepracor’s Depression Drug Has Investors Gloomy), on that day the stock was down nearly 20% after two trials had been less than impressive. However, at that time we reiterated that this stock was simply too cheap, se...
|
Options Update; Sepracor Sept volatility at 55, Oct at 57, Jan at 41 on buyout report
July 5: The week that was and the week ahead
|
|
|
Stocks in the news:
Boeing (BA) delivered 125 commercial aircraft in the second quarter. That's only one less than a year ago.
Sepracor (SEPR) early phase II studies of its depression treatment...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
|
Options Update: Sepracor volatility low into product pipeline setbacks
Filed under: Options  Sepracor (NASDAQ: SEPR) is recently down $2.89 to $15 in pre-open trading. SEPR announced that SEP-225289 failed to meet its primary endpoint in a pivotal Phase 2 trial in patients with major depressive disorder. SEPR also announced the FDA has put two Lunesta pediatric studies on hold due to concerns about non-clinical data that could be relevant to the use of Lunesta in children. SEPR over all option implied volatility of 48 is below its 26-week average of 57, according to Track Data, suggesting decreasing price movement.
<>NASDAQ 100 - QQQQ overall implied volatility at...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on SEPR |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Sepracor Inc
- Answers.com
Sepracor Inc.
